Download PDF
Exp Clin Endocrinol Diabetes 2015; 123(08): 500-507
DOI: 10.1055/s-0035-1554654
Article
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Commonly Used Antidiabetic Drugs on Antioxidant Enzymes and Liver Function Test Markers in Type 2 Diabetes Mellitus Subjects – Pilot Study

A. Ghadge   *
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
,
S. Harke   *
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
,
S. Khadke   *
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
,
A. Diwan
2   Bharati Vidyapeeth Medical College and Hospital, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India
,
M. Pankaj
2   Bharati Vidyapeeth Medical College and Hospital, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India
,
O. Kulkarni
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
,
P. Ranjekar
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
,
A. Harsulkar
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
,
A. A. Kuvalekar
1   Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India
› Author Affiliations
Further Information

Publication History

received 04 May 2015
first decision 20 May 2015

accepted 20 May 2015

Publication Date:
27 July 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: The present study analyzed the effects of antidiabetic drugs on antioxidant enzymes and liver function test (LFT) markers and their association with homeostatic model assessment of insulin resistance (HOMA-IR) in type 2 diabetic subjects.

Methods: We assessed healthy and diabetic subjects (100 each). Diabetic subjects were divided based on treatment with only metformin, metformin in combination with other antidiabetic drugs and insulin in combination with other antidiabetic drugs. LFT markers, antioxidant status and HOMA-IR were assessed in the subjects.

Results: Superoxide dismutase activity was higher (p<0.01) while catalase activity was lower (p<0.01) in the diabetic subjects as compared to controls. Serum glutamate-pyruvate transaminase (SGPT) (p<0.01) and bilirubin (p<0.05) levels were higher in diabetic male subjects while urea (p<0.05) levels were lower and SGPT (p<0.01) levels were higher in diabetic female subjects. In male subjects consuming only metformin, a positive association between HOMA-IR and insulin (p<0.05) was seen. A positive association between HOMA-IR and glucose (p<0.01), insulin (p<0.01), SOD (p<0.01) and SGPT (p<0.05) was seen in males receiving metformin with other drugs. Interestingly, the female subjects on metformin displayed a positive association between HOMA-IR and insulin (p<0.05) only. A positive association of HOMA-IR with glucose (p<0.01) and insulin (p<0.05) was seen in females on metformin in combination with other anti-diabetic drugs.

Conclusion: The alterations in the antioxidant enzyme activities and liver function tests are dependent upon the gender and glycemic status of subjects while the variations in correlations of HOMA-IR with antioxidant enzymes, liver function tests and inflammatory markers are dependent on type of treatments.

Key words

catalase - HOMA-IR - insulin - metformin - superoxide dismutase

* These authors contributed equally to this work


 

  • References

  • 1 Jandrić-Balen M, Bozikov V, Bistrović D et al. Antioxidant enzymes activity in patients with peripheral vascular disease, with and without presence of diabetes mellitus. Coll Antropol 2003; 27: 735-743
    PubMedGoogle Scholar
  • 2 Tho LL, Candlish JK, Thai AC. Correlates of diabetes markers with erythrocytic enzymes decomposing reactive oxygen species. Ann Clin Biochem 1988; 25: 426-431
    CrossrefPubMedGoogle Scholar
  • 3 Chatuphonprasert W, Lao-Ong T, Jarukamjorn K. Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide induced type 2-diabetes in mice by berberine and glibenclamide. Pharm Biol 2014; 52: 419-427
    CrossrefPubMedGoogle Scholar
  • 4 Zhu R, Wang Y, Zhang L et al. Oxidative stress and liver disease. Hepatol Res 2012; 42: 741-749
    CrossrefPubMedGoogle Scholar
  • 5 Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-834
    CrossrefPubMedGoogle Scholar
  • 6 Tolman KG, Fonseca V, Dalpiaz A et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-743
    CrossrefPubMedGoogle Scholar
  • 7 Lecube A, Hernandez C, Genesca J et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 1171-1175
    CrossrefPubMedGoogle Scholar
  • 8 Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192
    CrossrefPubMedGoogle Scholar
  • 9 Farrell GC, van Rooyen D, Gan L et al. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012; 6: 149-171
    CrossrefPubMedGoogle Scholar
  • 10 Takamatsu S, Noguchi N, Kudoh A et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 609-614
    PubMedGoogle Scholar
  • 11 Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002
    CrossrefPubMedGoogle Scholar
  • 12 Modi WS, Dean M, Seuanez HN et al. Monocyte derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Hum Genet 1990; 84: 185-187
    PubMedGoogle Scholar
  • 13 Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospectives Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012
    CrossrefPubMedGoogle Scholar
  • 14 Patel DK, Kumar R, Prasad SK et al. Antidiabetic and invitro antioxidant potential of Hybanthus enneaspermus (Linn) in streptozotocin-induced diabetic rats. Asian Pac J Trop Biomed 2011; 1: 316-322
    CrossrefPubMedGoogle Scholar
  • 15 Pareek H, Sharma S, Khajja BS et al. Evaluation of hypoglycemic and antihyperglycemic potential of Tridax procumbens (Linn.). BMC Complement Altern Med 2009; 9: 48
    CrossrefPubMedGoogle Scholar
  • 16 Thevenod F. Pathophysiology of diabetes mellitus type 2: roles of obesity, insulin resistance and B cell dysfunction. In: Masur K, Thévenod F, Zänker KS. (eds.). Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel: Karger; 2008. 19. 1-18
    Google Scholar
  • 17 Flockhart DA, Desta Z. Pharmacogenetics of drug metabolism. Clinical and Translational Science 2009; 301-317
    PubMedGoogle Scholar
  • 18 Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Women’s Health (Larchmt) 2005; 14: 19-29
    CrossrefPubMedGoogle Scholar
  • 19 Huang SM, Miller M, Toigo T et al. Evaluation of drugs in women. In: Principles of Gender Specific Medicine. Lagato MJ. (Ed.). Elsevier Academic Press; Oxford: 2007. 2. 848-859
    Google Scholar
  • 20 Alberti KG, Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO Consultation. Diabet Med 1998; 15: 539-553
    CrossrefPubMedGoogle Scholar
  • 21 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495
    Google Scholar
  • 22 Ghadge A, Khadke S, Harke S et al. Awareness Towards Type 2 Diabetes Mellitus In Urban Population Of Pune, Maharashtra, India. Int J Pharm Bio Sci 2013; 4: 1070-1075
    PubMedGoogle Scholar
  • 23 Ghadge AA, Harke SM, Khadke SP et al. Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antidiabetic drugs. Diabetes Metab Syndr 2014; 8: 230-232
    CrossrefPubMedGoogle Scholar
  • 24 Bunt JC, Krakoff J, Ortega E et al. Acute insulin response is an independent predictor of type 2 diabetes mellitus in individuals with both normal fasting and 2-h plasma glucose concentrations. Diabetes Metab Res Rev 2007; 23: 304-310
    CrossrefPubMedGoogle Scholar
  • 25 DeFronzo RA, Barzilia N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301
    CrossrefPubMedGoogle Scholar
  • 26 Pfützner A, Schöndorf T, Seidel D et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism 2006; 55: 20-25
    CrossrefPubMedGoogle Scholar
  • 27 Aydin A, Orhan H, Sayal A et al. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clinical Biochemistry 2001; 34: 65-70
    CrossrefPubMedGoogle Scholar
  • 28 Erejuwa OO, Sulaiman SA, Wahab MS et al. Antioxidant protective effect of glibenclamide and metformin in combination with honey in pancreas of streptozotocin-induced diabetic rats. Int J Mol Sci 2010; 11: 2056-2066
    CrossrefPubMedGoogle Scholar
  • 29 Kesavulu MM, Giri R, Kameswara Rao B et al. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. Diabetes Metab 2000; 26: 387-392
    PubMedGoogle Scholar
  • 30 Qujeq D, Rezvani T. Catalase (antioxidant enzyme) activity in streptozotocin-induced diabetic rats. Int J Diabetes & Metabolism 2007; 15: 22-24
    PubMedGoogle Scholar
  • 31 Bonnefont-Rousselot D, Raji B, Walrand M et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003; 52: 586-589
    CrossrefPubMedGoogle Scholar
  • 32 Passi S, Stancato A, Aleo E et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Bio factors 2003; 18: 113-124
    PubMedGoogle Scholar
  • 33 Wassmann S, Laufs U, Müller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305
    CrossrefPubMedGoogle Scholar
  • 34 Faure P, Rossini E, Wiernsperger N et al. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999; 48: 353-357
    CrossrefPubMedGoogle Scholar
  • 35 Rabbani SI, Devi K, Khanam S. Anti-mutagenic activity of metformin against the nicotinamide-streptozotocin induced dna damage in wistar rats. Int J Pharmacol Biol Sci 2009; 3: 141-148
    PubMedGoogle Scholar
  • 36 Mandave P, Rani S, Kuvalekar A et al. Antiglycation, antioxidant and antidiabetic activity of mature strawberry (fragaria×ananassa) fruits. International Journal of Applied Biology and Pharmaceutical Technology 2013; 4: 168-177
    PubMedGoogle Scholar
  • 37 Mandave PC, Pawar PK, Ranjekar PK et al. Comprehensive evaluation of in vitro antioxidant activity, total phenols and chemical profiles of two commercially important strawberry varieties. Scientia Horticulturae 2014; 172: 124-134
    CrossrefPubMedGoogle Scholar
  • 38 Rani S, Mandave P, Kuvalekar A et al. Antiglycation, antioxidant and antidiabetic activity of strawberry (fragaria×ananassa) fruits during ripening stages. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2014; 194-203
    PubMedGoogle Scholar
  • 39 Lacy F, Kailasam MT, O’Connor DT et al. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36: 878-884
    CrossrefPubMedGoogle Scholar
  • 40 Siddiqui A, Gulati R, Tauheed N et al. Correlation of waist-to-hip ratio (WHR) and oxidative stress in patients of acute myocardial infarction (AMI). Journal of Clinical and Diagnostic Research 2014; 8: 4-7
    PubMedGoogle Scholar
  • 41 Afzal M, Kazmi I, Gupta G et al. Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. Saudi Pharm J 2012; 20: 365-370
    CrossrefPubMedGoogle Scholar
  • 42 Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother 2010; 44: 1655-1659
    CrossrefPubMedGoogle Scholar
  • 43 Della-Morte D, Palmirotta R, Rehni AK et al. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics 2014; 15: 2063-2082
    CrossrefPubMedGoogle Scholar
  • 44 Bugudare US, Divakar K, Bai RK et al. Influence of hydroalcoholic extract of cinnamomum cassia on anti-diabetic effect of glibenclamide, metformin alone and their combination. Pharmacologyonline 2011; 2: 798-807
    PubMedGoogle Scholar
  • 45 Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696
    CrossrefPubMedGoogle Scholar
  • 46 Enjoji M, Kotoh K, Kato M et al. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. International Journal of Molecular Medicine 2008; 22: 521-527
    PubMedGoogle Scholar
  • 47 Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction-clinical strategies for treating oxidant stress. Am Heart J 2003; 146: 218-226
    CrossrefPubMedGoogle Scholar
  • 48 Maji D, Shaikh S, Solanki D et al. Safety of statins. Indian J Endocrinol Metab 2013; 17: 636-646
    PubMedGoogle Scholar
  • 49 Argo CK, Loria P, Caldwell SH et al. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology 2008; 48: 662-669
    CrossrefPubMedGoogle Scholar
  • 50 Zozuliñska D, Majchrzak A, Sobieska M et al. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 1999; 42: 117-118
    CrossrefPubMedGoogle Scholar
  • 51 Straczkowski M, Kowalska I, Nikolajuk A et al. Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance. Cardiovascular Diabetology 2003; 2: 5
    CrossrefPubMedGoogle Scholar